Research programme: autologous natural killer cell therapy - PDL BioPharma

Drug Profile

Research programme: autologous natural killer cell therapy - PDL BioPharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator PDL BioPharma
  • Class
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV, Injection)
  • 09 Dec 2008 Preclinical trials in Multiple myeloma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top